Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-12.9%)
USD 1.35
(-12.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.06 Million USD | 5.52% |
| 2022 | -3.09 Million USD | -3475.59% |
| 2021 | - USD | 76.02% |
| 2020 | -288.2 Thousand USD | 61.16% |
| 2019 | -879.33 Thousand USD | 30.51% |
| 2018 | -1.4 Million USD | 72.65% |
| 2017 | -13.85 Million USD | 28.3% |
| 2016 | -6.74 Million USD | 47.07% |
| 2015 | -48.35 Million USD | 27.89% |
| 2014 | -14.81 Million USD | -13.09% |
| 2013 | -17.45 Million USD | -181.83% |
| 2012 | -17.55 Million USD | -103.66% |
| 2011 | -1.81 Million USD | 33.9% |
| 2010 | -5.56 Million USD | -27.64% |
| 2009 | -3.21 Million USD | -378.88% |
| 2008 | -7.48 Million USD | 86.31% |
| 2007 | -4.87 Million USD | 7.13% |
| 2006 | -3.96 Million USD | 7.69% |
| 2005 | -6.27 Million USD | -24.95% |
| 2004 | -4.87 Million USD | -65.55% |
| 2003 | -2.94 Million USD | -82.69% |
| 2002 | -1.88 Million USD | 89.98% |
| 2001 | -4.03 Million USD | 51.27% |
| 2000 | -33.35 Million USD | -3865.76% |
| 1999 | -3.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -681.73 Thousand USD | -9.06% |
| 2024 Q2 | -522.08 Thousand USD | 23.42% |
| 2023 FY | - USD | 5.52% |
| 2023 Q2 | -845.4 Thousand USD | -1.94% |
| 2023 Q1 | -829.34 Thousand USD | 11.26% |
| 2023 Q3 | -763.15 Thousand USD | 9.73% |
| 2023 Q4 | -625.11 Thousand USD | 18.09% |
| 2022 Q1 | -370.09 Thousand USD | -416.51% |
| 2022 FY | - USD | -3475.59% |
| 2022 Q4 | -934.61 Thousand USD | -5.25% |
| 2022 Q3 | -888.02 Thousand USD | 1.64% |
| 2022 Q2 | -902.82 Thousand USD | -143.95% |
| 2021 Q2 | -6546.00 USD | -14.42% |
| 2021 Q1 | -5721.00 USD | 98.23% |
| 2021 Q4 | -71.65 Thousand USD | -961.35% |
| 2021 Q3 | -6751.00 USD | -3.13% |
| 2021 FY | - USD | 76.02% |
| 2020 FY | - USD | 61.16% |
| 2020 Q3 | -6254.00 USD | 0.0% |
| 2020 Q4 | -323.63 Thousand USD | -5074.83% |
| 2019 FY | - USD | 30.51% |
| 2019 Q2 | -357.01 Thousand USD | 39.14% |
| 2019 Q3 | -29.49 Thousand USD | 91.74% |
| 2019 Q4 | 75.06 Thousand USD | 354.49% |
| 2019 Q1 | -586.62 Thousand USD | -1164.83% |
| 2018 Q4 | -46.38 Thousand USD | 70.22% |
| 2018 FY | - USD | 72.65% |
| 2018 Q1 | -641.64 Thousand USD | 79.8% |
| 2018 Q3 | -155.76 Thousand USD | 72.38% |
| 2018 Q2 | -564.04 Thousand USD | 12.09% |
| 2017 Q3 | -1.11 Million USD | 80.46% |
| 2017 FY | - USD | 28.3% |
| 2017 Q1 | -1.37 Million USD | 21.31% |
| 2017 Q2 | -5.69 Million USD | -314.64% |
| 2017 Q4 | -3.17 Million USD | -185.35% |
| 2016 Q3 | -1.79 Million USD | -6.36% |
| 2016 Q1 | 925.2 Thousand USD | 16.8% |
| 2016 Q2 | -1.68 Million USD | -282.51% |
| 2016 FY | - USD | 47.07% |
| 2016 Q4 | -1.74 Million USD | 2.8% |
| 2015 FY | - USD | 27.89% |
| 2015 Q4 | 792.11 Thousand USD | -86.82% |
| 2015 Q3 | 6 Million USD | 168.71% |
| 2015 Q2 | -8.74 Million USD | -158.18% |
| 2015 Q1 | -3.38 Million USD | 23.36% |
| 2014 Q2 | 669.86 Thousand USD | 114.46% |
| 2014 Q3 | -4.98 Million USD | -844.86% |
| 2014 Q4 | -4.41 Million USD | 11.43% |
| 2014 FY | - USD | -13.09% |
| 2014 Q1 | -4.63 Million USD | -60.54% |
| 2013 Q2 | -4.43 Million USD | 5.14% |
| 2013 Q4 | -2.88 Million USD | 34.0% |
| 2013 FY | - USD | -181.83% |
| 2013 Q1 | -4.67 Million USD | -40.92% |
| 2013 Q3 | -4.37 Million USD | 1.29% |
| 2012 FY | - USD | -103.66% |
| 2012 Q3 | -4.57 Million USD | -122.8% |
| 2012 Q2 | -2.05 Million USD | 48.74% |
| 2012 Q1 | -4 Million USD | -1116.25% |
| 2012 Q4 | -3.31 Million USD | 27.58% |
| 2011 FY | - USD | 33.9% |
| 2011 Q2 | -1.65 Million USD | -24.85% |
| 2011 Q3 | -875.62 Thousand USD | 47.0% |
| 2011 Q4 | 394.28 Thousand USD | 145.03% |
| 2011 Q1 | -1.32 Million USD | -73.49% |
| 2010 FY | - USD | -27.64% |
| 2010 Q4 | -762.68 Thousand USD | 31.54% |
| 2010 Q3 | -1.11 Million USD | 22.27% |
| 2010 Q1 | -1.4 Million USD | -29.12% |
| 2010 Q2 | -1.43 Million USD | -2.32% |
| 2009 Q1 | -891.24 Thousand USD | -137.05% |
| 2009 Q2 | -881.7 Thousand USD | 1.07% |
| 2009 Q4 | -1.08 Million USD | -93.89% |
| 2009 Q3 | -559.47 Thousand USD | 36.55% |
| 2009 FY | - USD | -378.88% |
| 2008 Q3 | -923.59 Thousand USD | 26.69% |
| 2008 Q2 | -1.25 Million USD | -34.64% |
| 2008 Q1 | -935.73 Thousand USD | 16.72% |
| 2008 FY | - USD | 86.31% |
| 2008 Q4 | 2.4 Million USD | 360.47% |
| 2007 Q4 | -1.12 Million USD | 56.53% |
| 2007 FY | - USD | 7.13% |
| 2007 Q1 | -895.9 Thousand USD | 6.32% |
| 2007 Q3 | -2.58 Million USD | -281.18% |
| 2007 Q2 | -678.05 Thousand USD | 24.32% |
| 2006 Q1 | -728.73 Thousand USD | 32.39% |
| 2006 Q3 | -607.96 Thousand USD | 71.02% |
| 2006 Q4 | -956.39 Thousand USD | -57.31% |
| 2006 FY | - USD | 7.69% |
| 2006 Q2 | -2.09 Million USD | -187.92% |
| 2005 FY | - USD | -24.95% |
| 2005 Q1 | -1.42 Million USD | -5.37% |
| 2005 Q4 | -1.07 Million USD | 18.69% |
| 2005 Q3 | -1.32 Million USD | 46.03% |
| 2005 Q2 | -2.45 Million USD | -72.26% |
| 2004 Q1 | -969 Thousand USD | 28.5% |
| 2004 Q4 | -1.35 Million USD | -5.12% |
| 2004 Q3 | -1.28 Million USD | -1.96% |
| 2004 Q2 | -1.26 Million USD | -30.3% |
| 2004 FY | - USD | -65.55% |
| 2003 Q4 | -1.35 Million USD | -36.48% |
| 2003 FY | - USD | -82.69% |
| 2003 Q3 | -993.05 Thousand USD | 10.27% |
| 2003 Q2 | -1.1 Million USD | -63.57% |
| 2003 Q1 | -676.61 Thousand USD | -18.89% |
| 2002 FY | - USD | 89.98% |
| 2002 Q3 | -856.89 Thousand USD | -6.16% |
| 2002 Q4 | -793.16 Thousand USD | 34.59% |
| 2002 Q2 | -537.55 Thousand USD | -16.02% |
| 2002 Q1 | -706.45 Thousand USD | -19.08% |
| 2001 Q2 | -3.99 Million USD | 62.8% |
| 2001 Q4 | -593.24 Thousand USD | 57.13% |
| 2001 Q3 | -1.38 Million USD | 65.32% |
| 2001 Q1 | -2.16 Million USD | 41.57% |
| 2001 FY | - USD | 51.27% |
| 2000 Q3 | -5.09 Million USD | -48.33% |
| 2000 Q2 | -3.33 Million USD | 48.5% |
| 2000 Q1 | -6.48 Million USD | 0.0% |
| 2000 Q4 | -18.46 Million USD | -270.7% |
| 2000 FY | - USD | -3865.76% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.688% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 48.338% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.225% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 82.366% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.257% |
| Mesoblast Limited | -62.38 Million USD | 95.091% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -99.409% |
| Genus plc | 73.7 Million USD | 104.156% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 53.672% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 13.645% |
| Marizyme, Inc. | -34.28 Million USD | 91.065% |
| ContraFect Corporation | -64.99 Million USD | 95.288% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 65.082% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 32.327% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -118.505% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -15.828% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -31.81% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -491.263% |
| Accustem Sciences Inc. | -3.74 Million USD | 18.241% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.649% |
| EV Biologics, Inc. | -1.26 Million USD | -141.728% |
| Q BioMed Inc. | -617.62 Thousand USD | -395.932% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 185.751% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -384.343% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -34.079% |
| Biomind Labs Inc. | -1.03 Million USD | -196.073% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 131.012% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 57.228% |
| Skye Bioscience, Inc. | -13.54 Million USD | 77.391% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -105.929% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -12152.064% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 21.144% |
| IMV Inc. | -35.52 Million USD | 91.377% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 80.699% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -22.425% |
| GB Sciences, Inc. | -1.41 Million USD | -115.723% |
| Alpha Cognition Inc. | -9.7 Million USD | 68.441% |
| HST Global, Inc. | -5303.00 USD | -57660.06% |
| CSL Limited | 4.78 Billion USD | 100.064% |
| Halberd Corporation | -74.27 Thousand USD | -4023.663% |
| Enzolytics Inc. | -2.12 Million USD | -44.344% |
| Resverlogix Corp. | -11.74 Million USD | 73.914% |
| Affymax, Inc. | -14.29 Million USD | 78.573% |
| SYBLEU INC | -141.57 Thousand USD | -2063.59% |
| argenx SE | -216.02 Million USD | 98.582% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.465% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 351.686% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -104.35% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 908.516% |
| AVAX Technologies, Inc. | -6.11 Million USD | 49.89% |
| Zenith Capital Corp. | -8.6 Million USD | 64.408% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.768% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -17482.32% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -25.202% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1640.109% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 92.272% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -5.901% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -192.744% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 45653.48% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -75.03% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -59.456% |
| BioStem Technologies, Inc. | -7.55 Million USD | 59.45% |
| ONE Bio Corp. | 13.61 Million USD | 122.501% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1591.452% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -48.907% |
| Agentix Corp. | -1.37 Million USD | -123.292% |
| LadRx Corporation | 412.28 Thousand USD | 842.94% |
| Cell Source, Inc. | -4.27 Million USD | 28.309% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -734.107% |
| Regen BioPharma, Inc. | 1.46 Million USD | 308.943% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -226.914% |
| NovAccess Global Inc. | -1.03 Million USD | -196.002% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 134.595% |
| Itoco Inc. | -1.86 Million USD | -63.886% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -706.864% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -174.464% |
| Kadimastem Ltd | -2.62 Million USD | -16.714% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1180.793% |
| CytoDyn Inc. | -18.02 Million USD | 83.011% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3775.813% |
| Mobile Lads Corp. | -2.24 Million USD | -36.671% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -24947.15% |
| Qrons Inc. | -40.08 Thousand USD | -7542.065% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -530.668% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 680.74% |
| Rebus Holdings, Inc. | -951 Thousand USD | -222.084% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -188.417% |
| International Stem Cell Corporation | 202 Thousand USD | 1616.345% |
| Bioxytran, Inc. | -3.82 Million USD | 19.819% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5718.799% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -24.415% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 91.461% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -6706.702% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -11.871% |
| Neutra Corp. | -181.24 Thousand USD | -1589.968% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 84.806% |
| PureTech Health plc | -11.62 Million USD | 73.656% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 84.805% |
| IXICO plc | -707 Thousand USD | -333.241% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 60.143% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.664% |
| CSL Limited | 4.73 Billion USD | 100.065% |
| Cellectis S.A. | -92.63 Million USD | 96.693% |